The stock of Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) reached all time low today, Oct, 17 and still has $5.84 target or 12.00% below today’s $6.64 share price. This indicates more downside for the $141.99 million company. This technical setup was reported by Barchart.com. If the $5.84 PT is reached, the company will be worth $17.04M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 15,679 shares traded hands or 9.35% up from the average. Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) has declined 22.36% since March 14, 2016 and is downtrending. It has underperformed by 27.97% the S&P500.
Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) Ratings Coverage
Out of 5 analysts covering Nabriva Therapeutics (NASDAQ:NBRV), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Nabriva Therapeutics has been the topic of 6 analyst reports since October 12, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the stock with “Outperform” rating in Thursday, November 12 report. The firm has “Outperform” rating given on Tuesday, October 13 by Leerink Swann. Gabelli initiated the stock with “Buy” rating in Wednesday, January 27 report. Needham initiated Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) on Monday, October 12 with “Buy” rating. The firm has “Outperform” rating given on Tuesday, October 13 by RBC Capital Markets. Wedbush initiated Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) on Tuesday, October 13 with “Outperform” rating.
According to Zacks Investment Research, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria.”
More news for Nabriva Therapeutics AG – ADR (NASDAQ:NBRV) were recently published by: Benzinga.com, which released: “Leerink: Time To Buy Nabriva Therapeutics’ ‘Unique Differentiation'” on October 13, 2015. Marketwatch.com‘s article titled: “Some ‘cheap’ biotech stocks that could be buyout targets, RBC says” and published on January 25, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.